Although the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. Of note, the highest number of influenza-related deaths have occurred in the same US states for the past 4 years. Primary care providers, nurse practitioners, physician assistants, pharmacists, and other health care professionals can identify and help manage influenza in the community. However, better diagnostic modalities, more effective treatments, and practical methods to control the spread of influenza are needed. Although diagnostic tests for influenza exist and are currently being utilized, newer modalities are emerging that have promising advantages. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Clinicians who evaluate patients must keep apprised of new information regarding the diagnosis and treatment of influenza so they can incorporate this information into practice, reducing patient morbidity and mortality. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor baloxavir marboxil. This CME meeting series "Flu Forum: Are You Ready for the 2019-2020 Influenza Season?" will explore existing and newer diagnostic methods for influenza as well as approved antiviral agents regarding their novel mechanisms of action, ability to reduce duration of clinical illness and complications, and cessation of viral shedding. Clinical cases will be presented to highlight the key educational objectives.
|15 minutes||Diagnosing Flu – Current Approaches|
|25 minutes||Flu Treatment and Prophylaxis|
|20 minutes||Case Challenges in Flu|
|10 minutes||Question and Answer|
The intended audience for the activities this activity is internists, family practice physicians, nurse practitioners, physician assistants, pharmacists and other health care professionals involved in the management of patients with influenza.
Upon successful completion of this activity, participants should be better able to:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Vindico Medical Education designates this live activity for a maximum of AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This program is acceptable for 1.25 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-19-002-L01-P, effective 8/14/2019.
This program is acceptable for 1.25 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-20-009-L01-P, effective 10/20/2020. This is a knowledge-based activity and there is no fee to attend.
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.6 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20104555. This activity was planned in accordance with AANP Accreditation Standards and Policies.
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 10/20/2020 to 11/22/2020. AAPA reference number: CME-201356.
Unlabeled and Investigational Usage
The audience is advised that this activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
MIPS Qualifying Activity:
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities.
Disclaimer – Vindico Medical Education
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience. Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance.